Skip to main content
Clinical Trials/NCT06344325
NCT06344325
Completed
Phase 4

90% Effective Dose Study of Fospropofol Disodium in Induction and Maintenance of Anesthesia in Adults of Different Ages

Tongji Hospital1 site in 1 country330 target enrollmentMay 1, 2024
Interventionsfospropofol

Overview

Phase
Phase 4
Intervention
fospropofol
Conditions
Elective Surgery
Sponsor
Tongji Hospital
Enrollment
330
Locations
1
Primary Endpoint
Sedation score
Status
Completed
Last Updated
8 months ago

Overview

Brief Summary

Exploring the 90% effective dose (ED90) of fospropofol disodium in induction and maintenance of anesthesia in adults of different ages, providing more clinical evidence for the application of fospropofol disodium in clinical anesthesia

Detailed Description

As a newly marketed sedative hypnotic agent, fospropofol disodium is currently the only water-soluble precursor drug of propofol in China. It has the characteristics of long duration of action, low incidence of injection pain, respiratory and circulatory system related adverse events, and no lipid metabolism related adverse reactions, providing anesthesiologists with another sedative option during surgery. However, there are currently few clinical observation studies on this drug, and there have been no reports on its effective dosage in different age groups. Therefore, this study aims to observe the 90% effective dose (ED90) in anesthesia induction and maintenance in adults of different ages, providing effective clinical evidence for its application in clinical anesthesia.

Registry
clinicaltrials.gov
Start Date
May 1, 2024
End Date
February 28, 2025
Last Updated
8 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

aijun xu

Clinical Professor

Tongji Hospital

Eligibility Criteria

Inclusion Criteria

  • Aged 18-80 years old, elective surgery under general anesthesia.
  • ASA I-II;
  • Surgical duration\>30 minutes;
  • Sign an informed consent form.

Exclusion Criteria

  • American Society of Anesthesiologists(ASA)≥ III;
  • Body mass index (BMI)\<18 kg/m2 or\>30 kg/m2;
  • Individuals with a history or potential history of drug abuse or alcohol dependence;
  • Preoperative use of sedative or analgesic drugs;
  • Individuals with severe liver and kidney dysfunction;
  • Individuals who are allergic or potentially allergic to propofol and lipids;
  • The types of surgeries that directly affect hemodynamics, such as large vessel surgery and other surgical procedures;
  • Patients with abnormal coagulation function, endocrine disorders, or other factors affecting hemodynamic status;
  • Participants in other clinical studies within the past 3 months;
  • researchers deemed it inappropriate for participants to participate in this study.

Arms & Interventions

Youth group

Youth group (18-45 years old)

Intervention: fospropofol

middle-aged group

middle-aged group (46-65 years old)

Intervention: fospropofol

elderly group

elderly group (66-80 years old)

Intervention: fospropofol

Outcomes

Primary Outcomes

Sedation score

Time Frame: 1 day

Sedation score (MOAA/S)

Secondary Outcomes

  • Postoperative adverse reactions(1 day)

Study Sites (1)

Loading locations...

Similar Trials